Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Webb

Showing results (241-250 of 323) with videos related to

Pageof 33
Sort By:
Life Sciences|February 28, 2012
Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout miceLowell Ling, Rhoda E Kuc, Janet J Maguire, et al.
American Journal of Hypertension|October 21, 2020
Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)Linsay McCallum, Katriona Brooksbank, Alex McConnachie, et al.
Hypertension (Dallas, Tex. : 1979)|June 11, 2019
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney DiseaseTariq E Farrah, Atul Anand, Peter J Gallacher, et al.
Cardiovascular Research|February 6, 2002
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in manIan B Wilkinson, Jonathan T Affolter, Sanne L de Haas, et al.
Journal of Medicinal Chemistry|June 21, 2013
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failureQingzhi Zhang, Philip Milliken, Agnieszka Kulczynska, et al.
British Journal of Pharmacology|January 20, 2015
Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injuryKarolina M Duthie, Patrick W F Hadoke, Nicholas S Kirkby, et al.
Hypertension (Dallas, Tex. : 1979)|November 25, 2015
Hypertensive Encephalopathy and Renal Failure in a Young ManRobert W Hunter, Anna F Dominiczak, Jamal Alwakeel, et al.
Optics Letters|June 1, 2016
Thermal effects on the photoelastic coefficient of polymer optical fibersAcheroy Sophie, Merken Patrick, Ottevaere Heidi, et al.
Emergency Medicine Journal : EMJ|August 24, 2025
Scottish and Newcastle Antiemetic Protocol (SNAP) 12-hour acetylcysteine regimen for paracetamol overdose reduces anaphylactoid reactions without compromising hepatic protection in all age groups: a secondary analysisChristopher Humphries, Janice Pettie, Bridget Agboola, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 5, 2021
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational StudiesThomas M Caparrotta, Andrew M Greenhalgh, Karen Osinski, et al.
Pageof 33

Showing results (241-250 of 323) with videos related to

Sort By:
Pageof 33
Life Sciences|February 28, 2012
Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout miceLowell Ling, Rhoda E Kuc, Janet J Maguire, et al.
American Journal of Hypertension|October 21, 2020
Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD)Linsay McCallum, Katriona Brooksbank, Alex McConnachie, et al.
Hypertension (Dallas, Tex. : 1979)|June 11, 2019
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney DiseaseTariq E Farrah, Atul Anand, Peter J Gallacher, et al.
Cardiovascular Research|February 6, 2002
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in manIan B Wilkinson, Jonathan T Affolter, Sanne L de Haas, et al.
Journal of Medicinal Chemistry|June 21, 2013
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failureQingzhi Zhang, Philip Milliken, Agnieszka Kulczynska, et al.
British Journal of Pharmacology|January 20, 2015
Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injuryKarolina M Duthie, Patrick W F Hadoke, Nicholas S Kirkby, et al.
Hypertension (Dallas, Tex. : 1979)|November 25, 2015
Hypertensive Encephalopathy and Renal Failure in a Young ManRobert W Hunter, Anna F Dominiczak, Jamal Alwakeel, et al.
Optics Letters|June 1, 2016
Thermal effects on the photoelastic coefficient of polymer optical fibersAcheroy Sophie, Merken Patrick, Ottevaere Heidi, et al.
Emergency Medicine Journal : EMJ|August 24, 2025
Scottish and Newcastle Antiemetic Protocol (SNAP) 12-hour acetylcysteine regimen for paracetamol overdose reduces anaphylactoid reactions without compromising hepatic protection in all age groups: a secondary analysisChristopher Humphries, Janice Pettie, Bridget Agboola, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 5, 2021
Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational StudiesThomas M Caparrotta, Andrew M Greenhalgh, Karen Osinski, et al.
Pageof 33